Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients, aged 5-17 years inclusive~* History of house dust mite-related allergic rhinitis for at least 1 year requiring regular intake of symptomatic treatment(s)~* Sensitised to D. pteronyssinus and/or D. farinae (positive skin prick test with wheal diameter greater than 3 mm and specific IgE level ≥ 0.7 kU/L)~Exclusion Criteria:~• Co-sensitization associated with clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites to which the patient will be exposed during the study, i.e. will notably be excluded~* patients sensitised to cat or dog allergens and regularly exposed to these allergens~* patients sensitised to aspergillus, cladosporium, alternaria~* patients sensitised to parietaria , ragweed, or mugwort, if this allergen is endemic to the region

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Dpte and Dfar Allergen Extract (Type: ACTIVE_COMPARATOR): None
- Placebo tablets (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).